帕金森病的生物标志物：现状与未来展望。
Biomarkers of Parkinson's disease: current status and future perspectives.
机构信息
Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
出版信息
Drug Discov Today. 2013 Feb;18(3-4):155-62. doi: 10.1016/j.drudis.2012.09.001. Epub 2012 Sep 11.
Abstract
This review summarizes major advances in biomarker discovery for diagnosis, differential diagnosis and progression of Parkinson's disease (PD), with emphasis on neuroimaging and biochemical markers. Potential strategies to develop biomarkers capable of predicting PD in the prodromal stage before the appearance of motor symptoms or correlating with nonmotor symptoms, an active area of research, are also discussed.
摘要
这篇综述总结了在帕金森病（PD）的诊断、鉴别诊断和进展方面的生物标志物发现的主要进展，重点介绍了神经影像学和生化标志物。还讨论了开发有潜力的生物标志物的潜在策略，这些生物标志物能够在运动症状出现之前的前驱期预测 PD，或者与非运动症状相关，这是一个活跃的研究领域。
相似文献
1
Biomarkers of Parkinson's disease: current status and future perspectives.帕金森病的生物标志物：现状与未来展望。
Drug Discov Today. 2013 Feb;18(3-4):155-62. doi: 10.1016/j.drudis.2012.09.001. Epub 2012 Sep 11.
2
New markers in Parkinson's disease.帕金森病的新标志物。
Adv Clin Chem. 2020;96:137-178. doi: 10.1016/bs.acc.2019.12.001. Epub 2020 Jan 2.
3
Biomarkers in Parkinson's disease: Advances and strategies.帕金森病中的生物标志物：进展与策略
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1(Suppl 1):S106-10. doi: 10.1016/j.parkreldis.2015.09.048. Epub 2015 Sep 30.
4
The Concept of Prodromal Parkinson's Disease.帕金森病前驱期的概念。
J Parkinsons Dis. 2015;5(4):681-97. doi: 10.3233/JPD-150685.
5
Biomarkers of cognitive decline in Parkinson's disease.帕金森病认知功能减退的生物标志物
Parkinsonism Relat Disord. 2015 May;21(5):431-43. doi: 10.1016/j.parkreldis.2015.02.010. Epub 2015 Feb 20.
6
Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease.帕金森病前驱期和早期的影像学生物标志物。
J Parkinsons Dis. 2024;14(s2):S353-S365. doi: 10.3233/JPD-230385.
7
Combining Biomarkers with Genetics In Prodromal/Earliest Phase Parkinson's Disease.将生物标志物与遗传学相结合用于前驱期/极早期帕金森病。
J Parkinsons Dis. 2024;14(s2):S345-S351. doi: 10.3233/JPD-240155.
8
Biomarkers of Parkinson's Disease: An Introduction.帕金森病的生物标志物：简介
Int Rev Neurobiol. 2017;132:183-196. doi: 10.1016/bs.irn.2017.03.003. Epub 2017 May 3.
9
Biomarkers of Nonmotor Symptoms in Parkinson's Disease.帕金森病非运动症状的生物标志物
Int Rev Neurobiol. 2017;133:259-289. doi: 10.1016/bs.irn.2017.05.020. Epub 2017 Jun 27.
10
From Rapid Eye Movement Sleep Behavior Disorder to Parkinson's Disease: Possible Predictive Markers of Conversion.从快速眼动睡眠行为障碍到帕金森病：可能的转化预测标志物。
ACS Chem Neurosci. 2019 Feb 20;10(2):824-827. doi: 10.1021/acschemneuro.8b00388. Epub 2018 Oct 1.
引用本文的文献
1
Development of a hydroxyflavone-labelled 4554W peptide probe for monitoring αS aggregation.羟基黄酮标记的 4554W 肽探针用于监测 αS 聚集的研究进展。
Sci Rep. 2023 Jul 6;13(1):10968. doi: 10.1038/s41598-023-37655-3.
2
The reconfiguration pattern of individual brain metabolic connectome for Parkinson's disease identification.用于帕金森病识别的个体脑代谢连接组的重构模式。
MedComm (2020). 2023 Jun 27;4(4):e305. doi: 10.1002/mco2.305. eCollection 2023 Aug.
3
Serum metabolomics analysis revealed metabolic disorders in Parkinson's disease.血清代谢组学分析揭示了帕金森病中的代谢紊乱。
Medicine (Baltimore). 2023 Jun 9;102(23):e33715. doi: 10.1097/MD.0000000000033715.
4
Blunt dopamine transmission due to decreased GDNF in the PFC evokes cognitive impairment in Parkinson's disease.由于前额叶皮质中胶质细胞源性神经营养因子（GDNF）减少导致多巴胺传递减弱，引发帕金森病的认知障碍。
Neural Regen Res. 2023 May;18(5):1107-1117. doi: 10.4103/1673-5374.355816.
5
Multilayer Exponential Family Factor models for integrative analysis and learning disease progression.多层指数族因子模型用于综合分析和学习疾病进展。
Biostatistics. 2023 Dec 15;25(1):203-219. doi: 10.1093/biostatistics/kxac042.
6
Brain age vector: A measure of brain aging with enhanced neurodegenerative disorder specificity.脑龄向量：一种增强神经退行性疾病特异性的大脑老化测量指标。
Hum Brain Mapp. 2022 Nov;43(16):5017-5031. doi: 10.1002/hbm.26066. Epub 2022 Sep 12.
7
The Metabolomic Approach Reveals the Alteration in Human Serum and Cerebrospinal Fluid Composition in Parkinson's Disease Patients.代谢组学方法揭示帕金森病患者血清和脑脊液成分的改变。
Pharmaceuticals (Basel). 2021 Sep 17;14(9):935. doi: 10.3390/ph14090935.
8
Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization.帕金森病：用于诊断、疾病风险评估和药物治疗个体化的现有临床及有前景的组学检测方法
Diagnostics (Basel). 2020 May 25;10(5):339. doi: 10.3390/diagnostics10050339.
9
A Fully Automatic Framework for Parkinson's Disease Diagnosis by Multi-Modality Images.一种基于多模态图像的帕金森病全自动诊断框架。
Front Neurosci. 2019 Aug 23;13:874. doi: 10.3389/fnins.2019.00874. eCollection 2019.
10
Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson's disease models.HIP2 表达减少导致帕金森病模型运动功能障碍和多巴胺能神经元变性易感性增加。
Cell Death Dis. 2018 Oct 3;9(10):1020. doi: 10.1038/s41419-018-1066-z.
本文引用的文献
1
A molecular signature in blood identifies early Parkinson's disease.血液中的分子特征可识别早期帕金森病。
Mol Neurodegener. 2012 May 31;7:26. doi: 10.1186/1750-1326-7-26.
2
Association of serum uric acid levels with the progression of Parkinson's disease in Chinese patients.血清尿酸水平与中国帕金森病患者病情进展的相关性。
Chin Med J (Engl). 2012 Feb;125(4):583-7.
3
Phosphorylated α-synuclein in Parkinson's disease.帕金森病中的磷酸化α-突触核蛋白。
Sci Transl Med. 2012 Feb 15;4(121):121ra20. doi: 10.1126/scitranslmed.3002566.
4
Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers.脑脊髓液淀粉样蛋白β和tau 在 LRRK2 突变携带者中的变化。
Neurology. 2012 Jan 3;78(1):55-61. doi: 10.1212/WNL.0b013e31823ed101. Epub 2011 Dec 14.
5
Do we still need to develop new imaging biomarkers of dopamine denervation for Parkinson's disease?我们是否仍需要开发用于帕金森病的多巴胺去神经支配的新成像生物标志物？
Exp Neurol. 2012 Jan;233(1):118-20. doi: 10.1016/j.expneurol.2011.10.008. Epub 2011 Oct 20.
6
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function.DJ-1 和 αSYN 在 LRRK2 CSF 中与纹状体多巴胺能功能不相关。
Neurobiol Aging. 2012 Apr;33(4):836.e5-7. doi: 10.1016/j.neurobiolaging.2011.09.015. Epub 2011 Oct 21.
7
Imaging biomarkers in Parkinson's disease.帕金森病的影像学生物标志物。
Prog Neurobiol. 2011 Dec;95(4):614-28. doi: 10.1016/j.pneurobio.2011.08.009. Epub 2011 Aug 30.
8
[Expression of GSK3B gene in peripheral blood in patient with Parkinson's disease].[帕金森病患者外周血中GSK3B基因的表达]
Mol Biol (Mosk). 2011 May-Jun;45(3):459-63.
9
Amyloid-β and τ biomarkers in Parkinson's disease-dementia.帕金森病痴呆中的淀粉样β和τ 生物标志物。
J Neurol Sci. 2011 Nov 15;310(1-2):25-30. doi: 10.1016/j.jns.2011.06.046. Epub 2011 Jul 20.
10
Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons.黑质回声增强与帕金森病风险：一项针对1847名老年人的为期37个月的三中心研究
Arch Neurol. 2011 Jul;68(7):932-7. doi: 10.1001/archneurol.2011.141.
Zotero 插件